CAMP4 Therapeutics Q3 loss per share misses analyst expectations
CAMP•CAMP4 Therapeutics reported a Q3 loss of $0.37 per share, versus analyst expectations of $0.19. Its net loss widened mainly because of a non-cash loss from a change in derivative liability fair value; the company had $124.5 million in cash at quarter-end.
1. Quarterly results
CAMP4 Therapeutics reported a Q3 loss per share of $0.37, missing the $0.19 consensus estimate from 10 analysts. Income from operations was negative $14.03 million, and operating expenses were $15.93 million.
2. Cash and outlook
The company completed a $50.1 million private placement and had $124.5 million in cash at the end of Q3. It expects its cash runway to fund operations through the end of 2028 and remains on track to dose the first patient in its ASCEND trial by year-end 2026.
3. Program plans
CAMP4 expects to select a development candidate for its SHANK3 program for Phelan-McDermid syndrome in 2027. Higher research and development expenses reflected clinical and preclinical study costs for initiating the ASCEND Phase 1/2 trial.
